Synovo GmbH
General information
Synovo GmbH
Paul-Ehrlich Str. 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Michael Burnet, Managing Director
Company main phone: +49 (7071) 964325
Company main fax: +49 (7071) 964326
Website: https://www.synovo.com
Paul-Ehrlich Str. 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Michael Burnet, Managing Director
Company main phone: +49 (7071) 964325
Company main fax: +49 (7071) 964326
Website: https://www.synovo.com
| Year founded: | 2004 |
| Source of foundation: | Independent foundation |
Corporate description / mission:
Synovo is a drug discovery company with a primary focus on inflammation and innate immune processes. The main candidate, SYD003, is an Orphan Drug designated for the treatment of pancreatic cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Synovo is a drug discovery company with a primary focus on inflammation and innate immune processes. The main candidate, SYD003, is an Orphan Drug designated for the treatment of pancreatic cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
State of ownership: Private / independent
Headquarters: Yes
Headquarters: Yes
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 8 | |
| Phase I: | 1 |
Number of Medtech Products
| In development: | 1 |
Description of products:
SYD0073
SYD003
SYD0073
SYD003
© 2023 Biotechgate by Venture Valuation